Amarin Corp plcAMRNEarnings & Financial Report
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Revenue
$72.7M
Gross Profit
$50.4M
Operating Profit
$-16.0M
Net Profit
$-14.1M
Gross Margin
69.2%
Operating Margin
-22.0%
Net Margin
-19.4%
YoY Growth
7.8%
EPS
$-0.03
Amarin Corp plc Q2 FY2025 Financial Summary
Amarin Corp plc reported revenue of $72.7M (up 7.8% YoY) for Q2 FY2025, with a net profit of $-14.1M (down 1029.0% YoY) (-19.4% margin). Cost of goods sold was $22.4M, operating expenses totaled $66.3M.
Key Financial Metrics
| Total Revenue | $72.7M |
|---|---|
| Net Profit | $-14.1M |
| Gross Margin | 69.2% |
| Operating Margin | -22.0% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Amarin Corp plc Q2 FY2025 revenue of $72.7M breaks down across 2 segments, led by Products at $46.6M (64.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $46.6M | 64.1% |
| Licensing And Royalty | $26.1M | 35.9% |
Amarin Corp plc Revenue by Segment — Quarterly Trend
Amarin Corp plc revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Licensing And Royalty) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Products | — | $46.5M | $48.6M | $46.6M |
| Licensing And Royalty | — | — | $1.1M | $26.1M |
Amarin Corp plc Annual Revenue by Year
Amarin Corp plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $213.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $213.6M |
| 2024 | $228.6M |
| 2023 | $306.9M |
| 2022 | $369.2M |
Amarin Corp plc Quarterly Revenue & Net Profit History
Amarin Corp plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $45.1M | +7.0% | $-10.5M | -23.3% |
| Q4 FY2025 | $49.2M | -21.0% | $-1.2M | -2.5% |
| Q3 FY2025 | $49.7M | +17.4% | $-7.7M | -15.6% |
| Q2 FY2025 | $72.7M | +7.8% | $-14.1M | -19.4% |
| Q1 FY2025 | $42.0M | -25.7% | $-15.7M | -37.4% |
| Q4 FY2024 | $62.3M | -16.6% | $-48.6M | -78.0% |
| Q3 FY2024 | $42.3M | -36.0% | $-25.1M | -59.4% |
| Q2 FY2024 | $67.5M | -15.8% | $1.5M | 2.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $42.3M | $62.3M | $42.0M | $72.7M | $49.7M | $49.2M | $45.1M |
| YoY Growth | -15.8% | -36.0% | -16.6% | -25.7% | 7.8% | 17.4% | -21.0% | 7.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $799.9M | $750.6M | $685.3M | $655.7M | $670.1M | $659.8M | $670.8M | $645.8M |
| Liabilities | $248.0M | $219.2M | $199.2M | $182.0M | $205.2M | $200.9M | $211.5M | $196.4M |
| Equity | $551.9M | $531.4M | $486.2M | $473.7M | $464.9M | $458.9M | $459.3M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-2.7M | $-2.4M | $-13.3M | $-12.5M | $16.6M | $-12.7M | $15.3M |